Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

FDC Ltd

₹ 390-0.43%
14 Jan – close price
🔗fdcindia.com•BSE: 531599•NSE: FDC
Market Cap₹ 6,347 Cr.
Current Price₹ 390
High / Low₹ 528
Stock P/E26.9
Book Value₹ 150
Dividend Yield1.28 %
ROCE16.4 %
ROE12.1 %
Face Value₹ 1.00
Sales₹ 2,045 Cr.
OPM13.4 %
Mar Cap₹ 6,347 Cr.

ABOUT

FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets.[1]

KEY POINTS

Revenue BreakupAnti-infective medicines contribute 42% of revenues, followed by gastro intestinal 24%, vitamins/ minerals 7%, ophthalmology 6%, cardiac 7%, dermatology 4% and others 11%.[1]

Also present in buckets:
Aggressive Growth TriggersAsset Base ExpansionCapacity Expansion And ProductsRevenue Guidance Vs ActualsRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1700.7035.35408054.900.943124.952.5614478.318.9320.2154964.0130.1211543.963117.955.2412.970.07
2.Divi's Lab.6355.5067.89168718.560.47689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.9513.530.01
3.Torrent Pharma.4003.7062.54135503.400.80591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.0413.260.33
4.Cipla1434.5021.30115874.780.911353.373.737589.447.6422.7228349.5725.405441.141351.173.5214.720.01
5.Lupin2195.9023.19100308.450.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.1112.410.32
6.Dr Reddy's Labs1186.5017.1699028.890.671336.807.288828.309.8322.6934310.0024.645772.201347.102.7512.950.16
7.Mankind Pharma2244.4052.9992649.970.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.516.068.890.55
8.FDC389.8526.866347.151.2829.48-60.15461.74-8.5816.352044.8813.45236.3429.482.6010.290.01
–Median: 149 Co.394.529.561738.640.1213.4911.71161.7610.5814.89591.7315.9345.2613.963.148.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
446407431530480452454624505459482642462
Expenses
395360377410401370396482433413429501427
Operating Profit
51475412079825814272465314135
Other Income
29191030272521283519313621
Profit before tax
69545313995966715892506816139
Tax %
25%27%30%22%24%19%28%27%20%28%29%24%25%
Net Profit
51393710972784811574364812229
EPS in Rs
3.092.382.246.544.424.812.967.064.542.242.967.511.81

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
8368779861,0081,0611,0741,3281,3231,5161,7771,9162,0702,045
Expenses
6306807597668358541,0339991,2691,5221,5781,7501,770
Operating Profit
206197227242225220295324247255338320275
Other Income
38444044455171977954103106107
Interest
3211113334444
Depreciation
25383435353337383739405459
Profit before tax
217201232250234236325380285266398368318
Net Profit
134146169187168172247294220201307274236
EPS in Rs
7.568.209.5010.529.659.8414.4317.4513.0112.1118.8716.8114.52
Dividend Payout %
30%28%24%21%0%0%6%0%0%0%0%30%–

Compounded Sales Growth

10 Years:9%
5 Years:9%
3 Years:11%
TTM:0%

Compounded Profit Growth

10 Years:7%
5 Years:2%
3 Years:7%
TTM:-25%

Stock Price CAGR

10 Years:7%
5 Years:4%
3 Years:14%
1 Year:-19%

Return on Equity

10 Years:14%
5 Years:13%
3 Years:12%
Last Year:12%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
18181818181817171717161616
Reserves
8239121,0591,2461,2451,4161,5251,7051,9321,9642,0812,2712,421
Borrowings
11111115143128202121
Other Liabilities
209209181195224192249207274327341402420
Total Liabilities
1,0511,1401,2591,4591,4881,6251,8061,9432,2542,3352,4592,7102,878
Fixed Assets
272381671674670678670685701695676848836
Gross Block
454.57613.76704.26742.10772.29813.68840.73890.57942.26971.79985.511,175.85–
Accumulated Depreciation
182.43232.3933.3667.61102.53135.21170.96205.56241.29276.86309.12328.35–
CWIP
182920613122419104198261136163
Investments
4234963254914725856657908868068501,0501,028
Other Assets
338234243287333349447448563637672677850
Total Assets
1,0511,1401,2591,4591,4881,6251,8061,9432,2542,3352,4592,7102,878

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
149127171153148104239210162165221310
Cash from Investing Activity
-55-89-73-14420-109-85-84-1474-18-199
Cash from Financing Activity
-75-47-970-169-0-142-126-10-180-202-92
Net Cash Flow
19-10110-2-612-15-11119

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
272524282628343019252218
Inventory Days
115133134148166183180189210180217185
Days Payable
91958581101821016894100104102
Cash Conversion Cycle
5164739592130113151135106134102
Working Capital Days
31222242844414745485233
ROCE %
25%21%22%21%19%18%22%22%15%13%18%16%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
69.49%69.49%69.49%69.66%69.66%69.66%69.66%69.66%69.66%69.66%69.66%69.66%
FIIs
3.77%3.80%2.06%2.42%2.43%2.65%2.51%2.62%2.67%2.56%2.41%2.43%
DIIs
7.76%8.27%9.13%8.12%7.76%6.94%6.72%6.02%6.08%6.37%7.17%6.81%
Public
18.98%18.44%19.32%19.80%20.15%20.76%21.11%21.71%21.60%21.42%20.76%21.10%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

FDC Limited Submits SEBI Dematerialisation Compliance Certificate for March Quarter

10th April 2026, 4:15 pm

FDC Limited Closes Trading Window Ahead of Financial Results Announcement

26th March 2026, 11:16 pm

FDC Limited Reconstitutes Board Committees, MD to Become Chairman & Managing Director from April 1, 2026

21st March 2026, 12:12 am

FDC Board Appoints New Director, Re-constitutes Committees

18th March 2026, 8:25 pm

SEBI Takeover Disclosure: Aditi C Bhanot Acquires 6.12% Stake in FDC Limited via Inter-se Transfer, Exempted from Open Offer

20th February 2026, 4:01 pm

Published by Other Websites

External media mentions & references

FDC Sues J&J/Kenvue Over Enerzal vs eRZL Naming Dispute

8th April 2026, 8:23 pm

US Tariff Threat Hits Indian Pharma Stocks Hard, Index Down 3%

2nd April 2026, 11:10 am

Dividend Rush: 30+ Indian Stocks Turn Ex-Dividend Next Week

6th February 2026, 1:04 pm

FDC, GR Infra, Laurus Labs Surge Pre-Open Amid Market Demand, No News

6th January 2026, 9:23 am

India Pharma Surges 8.6%! But What's Behind The Growth & Which Stocks Are Winning (And Losing)?

15th December 2025, 5:27 pm

News Articles

Editorial & research coverage

India Pharma Surges 8.6%! But What's Behind The Growth & Which Stocks Are Winning (And Losing)?
India Pharma Surges 8.6%! But What's Behind The Growth & Which Stocks Are Winning (And Losing)?

15th December 2025, 5:27 pm

Documents

Announcements

Announcement Under Regulation 30 (LODR) - ANDA Approval

9 Jan - FDA ANDA approval for Fluconazole Tablets USP 50/100/150/200 mg (announced Jan 9, 2026).

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation Under Regulation 30 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015

29 Dec - GST order Dec 29, 2025 demanding ₹15.61 crore (tax ₹8.42cr, interest ₹6.34cr, penalty ₹0.84cr).

Announcement under Regulation 30 (LODR)-Newspaper Publication

26 Dec - Copies of the newspaper advertisement regarding the Notice of Postal Ballot.

Closure of Trading Window

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Financial Year 2012

(from nse)

Credit Ratings

No credit ratings.

Concalls

Nov 2023

TranscriptPPTRecording

Feb 2023

PPT

Nov 2022

Transcript

Nov 2022

TranscriptPPT

Aug 2022

TranscriptPPT

May 2022

TranscriptPPT

Feb 2022

Transcript

Dec 2021

Transcript

Jun 2017

PPT

Nov 2016

PPT

May 2016

PPT

Stock Analysis

Description

  1. FDC Limited is a fully integrated pharmaceutical company established in 1936, renowned as a pioneer in specialized formulations and a leading global manufacturer of Oral Rehydration Salts (ORS). The company markets its products, including brands like Zifi and Electral, across domestic and international markets.

Key Growth Triggers

  1. US FDA ANDA approval for Fluconazole Tablets USP across multiple strengths grants FDC market access in the United States, a key strategic objective for global expansion.
  2. This follows previous US FDA approval for Pilocarpine Hydrochloride Ophthalmic Solution, indicating a focused effort on expanding its product portfolio and market reach in the lucrative US ophthalmology segment.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. Q2 FY26 consolidated PAT saw a significant year-on-year decline of approximately 60.6%, with EBITDA margins contracting to 7.5% due to higher R&D and employee costs.
  2. The company received a GST demand notice of ₹15.61 crore for FY 2021-22, citing misclassification of tax rates, although FDC plans to contest it and does not foresee material financial impact.

Key Dates To Watch

  1. Postal ballot results for the proposed relocation of the registered office to Mumbai are expected by January 29, 2026.

Corporate Announcements

10th Apr 26
Impact Rating: 5
FDC Limited has submitted a confirmation certificate to stock exchanges from its registrar, MUFG Intime India, verifying compliance with SEBI rules for dematerialization in the quarter ended March 31, 2026.
26th Mar 26
Impact Rating: 4
FDC Limited will be closing its trading window for dealing in the company's securities from April 1, 2026. This closure is in compliance with SEBI regulations and will remain in effect until 48 hours post the announcement of its audited financial results.
20th Mar 26
Impact Rating: 7
Following CA Uday Kumar Gurkar's tenure completion, FDC Limited has updated its board committee compositions. Mr. Mohan Chandavarkar, currently MD, will take on the dual role of Chairman & Managing Director effective April 1, 2026.
18th Mar 26
Impact Rating: 6
FDC Limited's board has noted the cessation of CA Uday Kumar Gurkar and approved the appointment of CA Kishore Saletore as an Additional Independent Director for a 5-year term starting April 1, 2026.
20th Feb 26
Impact Rating: 8
Regulatory filing details an inter-se transfer of FDC Limited shares among promoter group members.